In late 2025, Wilmington PharmaTech, a US-based active parmaceutical ingredient (API), announced a partnership with Curewell Capital, a healthcare-focused private equity firm, to support the company’s continued expansion. Kent Payne, PhD, Managing Director at Wilmington, reported on the company’s plans to invest $50 million to further build out its facility in Glasgow, Delaware, at the DCAT Member Company Announcement Forum, held March 23, 2026, at DCAT Week.

The expansion will more than double its current reactor capacity through the addition of two 10,000-liter suites. When those suites come online in 2027, Wilmington will expand its ability to produce commercial‑scale small‑molecule APIs and peptides. The company has been investing in US-based API capacity for the last several years, and this development marks the second phase of a multi‑year effort to grow its US footprint, having already completed a project to add dedicated suites for highly potent APIs (HPAPIs) in 2025 at its Delaware campus.

Wilmington PharmaTech’s operations are situated on a 54-acre campus in Newark, Delaware, a site with space, infrastructure, and zoning permissions that enable continued expansion. Wilmington runs two adjacent facilities on the campus: one focused on development and early clinical manufacturing, and the other focused on late stage scale-up and commercial suppl

As Wilmington Pharmatech accelerates its facility expansion, the company has also been expanding the leadership team Dr. Hui-Yin “Harry” Li, Ph.D., who built the organization from a small solid-state chemistry lab into a CRDMO, retains significant ownership and will continue to lead the business as CEO alongside the management team. Following the partnership with Curewell Capital, Wilmington added Kent Payne, PhD, a veteran three-time CEO of global CDMO operations, as Managing Director to provide leadership support for shift toward larger scale manufacturing operations. Additionally, earlier this year (20260, the company appointed Mike Shearer, a seasoned commercial leader known for expanding customer portfolios and building high‑performing business development teams, as Chief Commercial Officer.

Wilmington PharmaTech’s operations are situated on a 54-acre campus in Newark, Delaware, a site with space, infrastructure, and zoning permissions that enable continued expansion. Wilmington runs two adjacent facilities on the campus: one focused on development and early clinical manufacturing, and the other focused on late stage scale-up and commercial supply.